tirzepatide and psoriatic arthritis Combination Therapy Improves Outcomes in With Obesity Scratching the Surface: The Latest
Description
Journal of Strength and Conditioning Research, 36 (10), 29702981
Uncertain future for GLP-1 users as insurance limit reimbursements Byers lives in Michigan, but gets health insurance through an employer based in Pennsylvania
That convenience comes at a cost that isn't obvious at first
Multiple randomised, placebo-controlled trials have tested GLP-1 drugs as add-on therapy to insulin in people with T1D, and the picture that emerges is consistent, if modest: meaningful weight loss, real reductions in daily insulin needs, and improvements in CGM time in range
A third target is intestinal microbiomes and metabolic endotoxemia
